← Back to Search

Priming Intervention for Psoriasis

N/A

Waitlist Available

Led By Steven R Feldman

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Either diagnosed with psoriasis (ICD-9: 696.1) or a parent/caregiver of an individual diagnosed with psoriasis (ICD-9: 696.1).

Be older than 18 years old

Must not have

Already on or previously failed management attempts with an IL-23 inhibitor including ustekinumab, guselkumab, risankizumab, or Tildrakizumab, amongst others.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing how well patients do when given a choice of 3 different psoriasis treatments.

Who is the study for?

This trial is for English-speaking individuals with psoriasis or their caregivers. It's not open to those who have already tried and did not respond well to specific biologic drugs like ustekinumab, guselkumab, risankizumab, or tildrakizumab.

What is being tested?

The study aims to understand how people with psoriasis feel about injectable biologic medications as a treatment option. Participants will be divided into groups receiving different educational interventions regarding these treatments.

What are the potential side effects?

Since the focus of this trial is on patient perceptions rather than medication effects, it does not directly involve drug side effects. However, discussions may cover potential side effects of biologics used in psoriasis management.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have psoriasis or I am caring for someone with psoriasis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have tried or am currently on an IL-23 inhibitor like ustekinumab without success.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Oral Survey Responses

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Group #3 (Intervention)Experimental Treatment1 Intervention

Group #3 (Intervention) Survey 3 will be administered, and patients will be asked the following primer: Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis. What do you think would be the best way to describe this to a patient? 1. Stelara® acts in an almost all-natural way to help control psoriasis. 2. Stelara® blocks one of the genetic causes of psoriasis. 3. Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance 4. Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)

Group II: Group #2 (Intervention)Experimental Treatment1 Intervention

Group #2 (Intervention) Survey 2 will be administered, and patients will be asked the following primer: Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis. How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)

Group III: Group #1 (Control)Active Control1 Intervention

Group #1 (Control) Oral survey 1 will be administered and patients will be asked: Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)

0 / 2Eligibility criteria met